Cencora Inc. (COR) — ESG & Values Scores

Environment story

Cencora discloses minimal direct environmental data. Scope 1 & 2 emissions are not reported in the 10-K; Scope 3 emissions are undisclosed (penalty: -15). No net-zero target year is disclosed (penalty: -15). The company operates distribution centers globally but provides no evidence of verified physical decarbonization infrastructure investments; capital expenditures focus on warehouse automation and technology, not renewable energy or emissions reduction (deduction for lack of initiative: 0 bonus). Cold-chain logistics expansion is noted without corresponding emissions-reduction commitments, suggesting rising operational carbon footprint risk. No material resource controversies (toxic waste, water) are disclosed. Greenwashing safeguards: company makes no claimed net-zero commitments that require scrutiny.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Distribution center automation and optimization

Company invests in warehouse automation and efficiency improvements to reduce operational costs; mentioned as ongoing capital expenditure focus.

May reduce per-unit energy intensity but no explicit emissions-reduction quantification provided.
Cold-chain logistics expansion

Volume of cold-chain storage and shipping has increased and company expects continued growth to support specialty pharmaceuticals and biologics.

Likely increases absolute energy consumption and carbon footprint; no mitigation strategy disclosed.

Social story

Cencora employs 51,000+ globally; ~41% U.S.-based; ~24% covered by collective bargaining agreements (nearly all non-U.S.). CEO-to-median-worker pay ratio is not disclosed; cannot assess penalty. No recent NLRB complaints, strikes, or union-suppression activities are documented in the 10-K (neutral standing on union relations; score unpenalized). Leadership diversity percentages are not disclosed; cannot quantify board/executive female or URM representation (deduction of 15 points applied for undisclosed diversity). Supply-chain labor practices: company mentions supply-chain oversight and regulatory compliance but does not detail human-rights audits, cobalt/lithium sourcing, or living-wage commitments. Employee benefits are comprehensive (health, paid leave, flexible work, tuition reimbursement, ERGs, wellness programs). Turnover rate is not disclosed. Safety programs exist (peer-to-peer safety, training, incentives) with no major incidents documented. Overall: strong stated commitment to employee experience and development; transparency gaps on diversity and supply-chain labor.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Employee development and talent retention programs

Leadership and professional development, executive coaching, tuition reimbursement, mentorship, employee resource groups (ERGs), recognition programs, personalized learning platform.

Supports career advancement and employee engagement; no quantified retention or promotion metrics provided.
Comprehensive benefits and wellness

Competitive compensation, health/insurance benefits, paid time off, flexible work arrangements, retirement/stock purchase plans, paid parental and caregiver leave, backup child/elder care.

Addresses physical, emotional, financial, and social wellness dimensions; varies by geographic location.
Team member safety programs

Peer-to-peer safety program, regular leader reviews of safety data, operational excellence scorecards, distribution center training on safety procedures, performance incentives.

Proactive safety culture; no specific incident rates or safety metrics disclosed.
Employee satisfaction surveys

Annual company-wide surveys to gauge employee satisfaction and identify areas for improvement.

Mechanism for employee voice and culture shaping; results and follow-up actions not disclosed.
Team Assistance Fund

Fund to help employees experiencing extreme financial hardship from catastrophic events.

Addresses employee financial crises; scope and utilization not quantified.

Governance story

Cencora operates under a standard single-class share structure with no disclosed dual-class voting inequalities (no penalty). Board independence percentage is not disclosed; cannot verify compliance with the 75% threshold (conservative deduction: -15 pending disclosure). Lobbying expenditures are not separately disclosed in the 10-K; company mentions participation in industry and governmental engagement but no specific anti-climate or anti-consumer-protection lobbying is documented (no penalty applied; marked as unknown). Regulatory and litigation activity: company faced significant opioid litigation ($4.3 billion accrued liability as of Sept 30, 2025, to be paid over 13 years); settled with 48 of 49 states and political subdivisions under the 2021 Distributor Settlement Agreement. No active antitrust, consumer-safety, or financial-fraud proceedings are detailed in the 10-K (prior settlements are now managed through accrual). Company faces ongoing regulatory scrutiny from DEA, FDA, and state pharmacy boards regarding supply-chain security, pedigree, and controlled-substance handling; described as operational and compliance risk, not active enforcement. No shareholder litigation for blocking climate proposals is documented. Governance tone emphasizes compliance, risk management, and regulatory alignment.

Criticisms on file

Opioid litigation and settlement: $4.3 billion accrued liability as of September 30, 2025, covering Distributor Settlement Agreement (48 of 49 eligible states) and other opioid-related settlements. Payments expected over 13 years.
Source: Cencora 10-K, Note 12 (Loss Contingencies) and Item 7 (MD&A – Commitments and Obligations)
Cybersecurity incidents: Company disclosed cybersecurity incidents in February 2024 and March 2023 involving data exfiltration; costs incurred but reported as non-material to financial results at time of disclosure.
Source: Cencora 10-K, Item 1A (Risk Factors – Loss or disruption of information systems) and MD&A (Restructuring and other expenses)
DEA inspections and regulatory scrutiny: Walgreens and Boots (25% of COR revenue) are subject to ongoing DEA inspections and monitoring for controlled-substance compliance; potential for revocation of controlled-substance registrations is identified as a material risk to COR's business.
Source: Cencora 10-K, Item 1A (Risk Factors – A disruption in our distribution or generic purchasing services arrangements with Walgreens or WBAD)

Disclosed initiatives

Regulatory compliance infrastructure

Investments in secure supply-chain information systems, DEA compliance, FDA pedigree tracking (DSCSA compliance), controlled-substance licensing and security standards.

Ongoing operational costs to meet pharmaceutical supply-chain regulations; company expects costs to increase with new FDA proposed rules and international regulations (e.g., EU Falsified Medicines Directive).
Cybersecurity and data privacy program

Global privacy compliance program addressing HIPAA, GDPR, PIPEDA, and emerging AI regulations. Investments in cybersecurity capabilities and cyber resiliency. Company experienced cybersecurity incidents in February 2024 and March 2023 (prior incidents did not have material impact).

Proactive risk management; ongoing costs to enhance security controls and monitor evolving threats.
Litigation and opioid settlement management

Settlement agreements under Distributor Settlement Agreement effective April 2, 2022; 48 of 49 eligible states and 99% by population of political subdivisions in settling states are parties. Payments structured over 13 years.

Provides long-term certainty on opioid-related liabilities; no material impact on dividend-payment ability.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of Cencora Inc.. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open Cencora Inc. in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)